Docusign Envelope ID: EC3FB640-0F7C-4E77-9D43-EE00D5BA2BEF **REGISTERED CHARITY NUMBER: 1174480** ## **REPORT OF THE TRUSTEES AND** **UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2025** **FOR** **ORCHARD** Archangel Accounting Burnham House Splash Lane Wyton Huntingdon PE28 2AF Docusign Envelope ID: EC3FB640-0F7C-4E77-9D43-EE00D5BA2BEF **ORCHARD** ## **CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2025** ||**Page**| |---|---| |**Report of the Trustees**|1 to 5| |**Independent Examiner's Report**|6| |**Statement of Financial Activities**|7| |**Balance Sheet**|8| |**Notes to the Financial Statements**|9 to 16| Docusign Envelope ID: EC3FB640-0F7C-4E77-9D43-EE00D5BA2BEF **ORCHARD** ## **REPORT OF THE TRUSTEES** ## **FOR THE YEAR ENDED 28 FEBRUARY 2025** The trustees present their report with the financial statements of the charity for the year ended 28 February 2025. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019). ## **OBJECTIVES AND ACTIVITIES** ## **Objectives and aims** Orchard is a charity focusing on developing treatments for patients suffering from obsessive-compulsive disorder (OCD), a serious mental illness. We work with academia, clinicians, pharmaceutical/biotech companies, government agencies, patients and other charities to fast-track the development of new and innovative treatments for OCD. OCD is a common, chronic and severely disabling mental illness that affects at least a million people in the UK alone. It is characterised by intrusive thoughts (obsessions) and accompanying rituals (compulsions) aimed at reducing anxiety and distress. Sixty per cent of OCD patients are also depressed and many are suicidal. The lifetime prevalence of OCD is 2- 3 %. It affects all population groups regardless of gender and culture. There is an urgent need for the development of new and better treatments, yet the field is severely underfunded. Very little research is carried out by the pharmaceutical industry, and funding for academic research is scarce and difficult to obtain. This is why we have set up Orchard in order to raise much-needed funding for OCD research. ## **Public benefit** In setting our objectives and planning our activities, the Trustees have given careful consideration to the Charity Commission's general guidance on public benefit. For the public benefit, the charitable objects are: 1. to promote and protect the physical and mental health of sufferers of OCD and related disorders, their families and carers including (but not limited to) through the provision of support, education and practical advice. 2. to improve the diagnosis, treatment and care of persons suffering from OCD and related disorders and their families and carers by facilitating, setting up and supporting (including (but not limited to) by way of funding) specialised and highly skilled, multi-disciplinary international teams to develop new and effective methods of diagnosis, treatment and management of and services for OCD and related disorders and to assist in the publication and dissemination of the useful results. 3. to assist in such ways as the charity Trustees think fit any charity whose aims include promoting and/or protecting the physical and mental health of sufferers of OCD and related disorders, their families and carers through the provision of funding, grants, support and practical advice. 4. to advance the education of the general public in all areas relating to OCD and related disorders and to raise awareness of and reduce the stigma related to OCD and related disorders and assist in such ways as the charity Trustees think fit including (but not limited to) through lectures, seminars, webinars, workshops, through the internet and social media and publication of newsletters and research papers and in any other ways in which the charity Trustees think fit. 5. to advance the education of the public in general (and particularly amongst healthcare professionals and scientists) on the subject of OCD and related disorders and to promote research for the public benefit in all aspects of that subject and to assist in the publication and dissemination of the useful results. The Trustees have complied with the duty in Section 4 of the 2011 Charities Act to have due regard to guidance published by the Charity Commission, including public benefit guidance. Page 1 Docusign Envelope ID: EC3FB640-0F7C-4E77-9D43-EE00D5BA2BEF **ORCHARD** ## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28 FEBRUARY 2025** ## **ACHIEVEMENT AND PERFORMANCE Key achievements, principal activities and fundraising** ## **Strengthening our team and governance** The financial year ending on February 28th, 2025, saw Orchard grow both its expertise and its capacity. We welcomed Dr Ana Maria Pereira de Souza as our new Fundraising & Communications Officer and appointed three new trustees – Dr Chiara Toschi, Dr Ilenia Pampaloni and Katherine Selby – adding lived experience, scientific and digital-media skills to the board. Two long-standing trustees - Vincenzo Garzya and Mr Neil Balmer - departed with thanks due to time commitment restrictions. ## **Foundation of the Orchard OCD College** The Orchard OCD College was created in March 2024. Working under the umbrella of Orchard OCD, the College comprises prominent researchers and clinicians in the field of Obsessive-Compulsive and Related Disorders (OCRD) working in the UK and internationally. With over 50 members, our goal is to advance understanding and improve health and wellbeing of people with Obsessive Compulsive and Related Disorders (OCRDs) through supporting research collaborations, raising awareness about OCRDs, and informing public policies. ## **Expanding the OCD Registry and digital outreach** Two short, animated films aimed respectively at young people and researchers went live in March 2024, supported by targeted social-media promotion both from Orchard OCD and the University of Hertfordshire. Registry enrolment rose steadily from 157 volunteers (11 studies) in February 2024 to over 250 volunteers by early 2025, averaging 5–10 new sign-ups each month. Work continues to encourage researchers to report back on recruitment numbers so that the Registry’s impact can be fully quantified. Trustees approved £45,000 to secure the Registry’s running costs for a further three years and earmarked the remaining £55,000 of a £100,000 budget for Ana Maria's salary over the next three years and a half. New Trustee Katherine Selby started to work with Ana Maria and Margherita on an enhanced social media strategy for Orchard in order to reach the widest possible public through all our social media channels, i.e., Instagram, LinkedIn, and Facebook. ## **Advancing our research portfolio** - _**Evaluating the effects of the 5-HT2A agonist psilocybin on the neurocognitive and clinical correlates of compulsivity: a pharmacological-challenge feasibility study**_ **(Psilocybin Study)** – Data collection was completed in June 2024, and data analyses showed a moderate-to-large effect after a single 10 mg dose of the compound in reducing compulsions. The paper resulting from the study has been submitted to _Comprehensive Psychiatry_ and is undergoing revision for publication. A larger, randomised controlled trial (budgeted at £3–4 million) is now in protocol development stage, with approaches to Norrsken Mind, the Wellcome Trust and Horizon Europe under way. - **Transcranial direct-current stimulation (tDCS) – FEATSOCS II** – Following the success of FEATSOCS 1 (FEasibility and Acceptability Of Transcranial Stimulation in Obsessive Compulsive Symptoms) in 2023, in partnership with the University of Hertfordshire and under the guidance of our trustee Prof. Naomi Fineberg, we have drafted and submitted two multimillion-grants to the UKRI/MRC to conduct a larger, randomised clinical trial (FEATSOCS II) testing the effectiveness of tDCS on OCD symptoms. The two applications have been unsuccessful, and we are now addressing reviewers' comments to re-purpose the application to a different funder. - **Double-Blind Randomised Placebo-controlled study of Tolcapone for OCD (Tolcapone Study)** – Recruitment for this study - led by Prof Jon Grant at the University of Chicago - progressed slightly more slowly than planned but is now expected to be completed by late Summer 2025. We receive interim feedback from the study team, and the next update is due for September 2025. Page 2 Docusign Envelope ID: EC3FB640-0F7C-4E77-9D43-EE00D5BA2BEF **ORCHARD** ## **REPORT OF THE TRUSTEES** ## **FOR THE YEAR ENDED 28 FEBRUARY 2025** - **Understanding the Role of Aberrant Memory Processing in the Relationship Between Trauma and Obsessive Compulsive Disorder (the Trauma & OCD study)** – Orchard-sponsored PhD project at the University of Cambridge has made considerable progress, with the first study being almost completed, and the protocols for the second and third being prepared for review by the University of Cambridge's Ethics Committee. Our sponsored PhD candidate – Margherita Zenoni - also submitted an application proposal to the International OCD Foundation for the 2025 Michael Jenike Young Investigator Award, for which she presented one of her PhD studies. - **Deep Brain Stimulation: A Cost-Saving Treatment Option for Extreme Treatment-Refractory Obsessive-Compulsive Disorder in the UK?** – In collaboration with Costello Medical, Dr Himanshu Tyagi, Prof Naomi Fineberg and Prof José Menchon, we conducted a study investigating the costeffectiveness of deep brain stimulation (DBS) as a treatment option for extreme treatment-refractory obsessive-compulsive disorder (TROCD) in the UK healthcare setting, specifically examining the costoffsets between DBS combined with maintenance treatments versus maintenance treatments alone. The study will be presented at ISPOR Europe - a high-profile conference in the field of health economics and outcomes research - in November 2025 and will shortly be submitted for publication. ## **Science Dissemination and Public Engagement** - **First OCD Research Conference for Patients and Families in the UK (London, Nov 2024)** – With the £20,000 grant obtained from the Awards For All England scheme in January 2024, we organised and delivered the first OCD Research Conference for Patients and Families in the UK. Over 100 patients and their families attended a day of accessible talks on cutting-edge research into OCD and the emergence of innovative treatments. We collected feedback from 96% of attendees, who overall rated the conference as "outstanding" and like something "unparalled" and "unprecedented" in the UK. - **Orchard OCD Lecture Series (Cambridge)** – A new public-lecture strand will launch in late 2025, opening with “What OCD can teach us about digital-age compulsions”. - **The OCD Conversations Podcast Series** – Our webinar programme was re-branded and upgraded to a broadcast-quality visual podcast, with episodes led by our trustee and TV broadcaster Sean Fletcher. We have launched the podcast series with an episode on Transcranial Focused Ultrasound Stimulation with Prof Elsa Fouragnan from the University of Plymouth. We are hosting a different scientist every month and each episode is then released on all the major podcast platforms as well as on YouTube. ## **FINANCIAL REVIEW** ## **Financial position** The charity is funded principally from donations. During the period donations of £3,292 (2024: £51,297) were received. Grants are sought for research into particular areas. During this financial year grants totaling £170,193 (2024: £50,000) were received. Expenditure during the period was £157,766 (2024: £148,912); leaving reserves of £271,026 (2024: £249,317) of which £26,097 (2024: £64,621) were restricted. ## **Reserves policy** The Trustees aim to maintain general reserves to cover, as a minimum, eight months of expenditure (covering salary costs and other general and administrative costs), net of depreciation. At the year end the general reserve was £166,529 (2024: £50,664), which is well in excess of the top end of this range. Page 3 Docusign Envelope ID: EC3FB640-0F7C-4E77-9D43-EE00D5BA2BEF ## **ORCHARD** ## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28 FEBRUARY 2025** ## **FUTURE PLANS** ## Research: The paper resulting from the Psilocybin study will be published and we will continue to work on the protocol for a larger, randomized clinical trial and on the funding applications to relevant funders. The Tolcapone study will be completed, and it will be written up for publication in a high impact factor scientific journal. We will continue to work on re-purposing the funding application for FEATSOCS II, a larger, randomised clinical trial testing the effectiveness of tDCS on OCD symptomatology. The Trauma & OCD PhD project will continue to progress, finalising its first study and collecting all the date for its second study, while preparing for the third and last study at the same time. The Deep Brain Stimulation Cost-Offset study conducted in collaboration with Costello Medical will be presented at ISPOR Europe in November 2025 and published in a high impact factor scientific journal. ## Hubs: Our OCD Registry will continue to be key in pushing forwards OCD research and facilitating and accelerating participant recruitment. We aim to expand internationally. The Orchard OCD College – as demonstrated since its inception in March 2024 – will serve as the main OCD research network in the UK, offering unique opportunities for new partnerships and research collaboration on new grant applications and projects in alignment with our charity’s mission of advancing scientific research into the understanding and treatment of OCD. ## Dissemination: With the launch of out podcast series “The OCD Conversations”, we will continue to disseminate cutting-edge OCD science in a lay-public-accessible way, aiming to reach the widest possible public. During the second half of 2025, we will launch a social media Raising Awareness Campaign aimed at demystifying common misconceptions about OCD, in order to educate the public about what OCD actually is, i.e., a serious psychiatric condition that can destroy lives. Page 4 Docusign Envelope ID: EC3FB640-0F7C-4E77-9D43-EE00D5BA2BEF **ORCHARD** ## **REPORT OF THE TRUSTEES FOR THE YEAR ENDED 28 FEBRUARY 2025** ## **STRUCTURE, GOVERNANCE AND MANAGEMENT** ## **Governing document** The charity constitutes a Charitable Incorporated Organisation and is governed by its governing document, registered on 1 September 2017 and amended on 7 September 2018. ## **REFERENCE AND ADMINISTRATIVE DETAILS** ## **Registered Charity number** 1174480 ## **Principal address** 66 Devonshire Road Cambridge CB1 2BL ## **Trustees** Dr N T Sireau PhD Mr V Garzya MBA (resigned) Mr S T Fletcher Dr N A Fineberg Mr N J Balmer (resigned) Mr P Chan (appointed 3 November 2023) ## **REFERENCE AND ADMINISTRATIVE DETAILS** ## **Independent Examiner** Archangel Accounting Burnham House Splash Lane Wyton Huntingdon PE28 2AF 04/07/2025 Approved by order of the board of trustees on ................................... and signed on its behalf by: .................................................................... ABAAB50153274BF... Dr N T Sireau PhD - Trustee Page 5 Docusign Envelope ID: EC3FB640-0F7C-4E77-9D43-EE00D5BA2BEF ## **INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF ORCHARD** ## **Independent examiner's report to the trustees of Orchard** I report to the charity trustees on my examination of the accounts of Orchard (the Trust) for the year ended 28 February 2025. ## **Responsibilities and basis of report** As the charity trustees of the Trust you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the Act'). I report in respect of my examination of the Trust's accounts carried out under Section 145 of the Act and in carrying out my examination I have followed all applicable Directions given by the Charity Commission under Section 145(5)(b) of the Act. ## **Independent examiner's statement** I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect: 1. accounting records were not kept in respect of the Trust as required by Section 130 of the Act; or 2. the accounts do not accord with those records; or 3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination. I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached. Julia Jones FCA Archangel Accounting Burnham House Splash Lane Wyton Huntingdon PE28 2AF ## 04/07/2025 Date: ............................................. Page 6 Docusign Envelope ID: EC3FB640-0F7C-4E77-9D43-EE00D5BA2BEF ## **ORCHARD** ## **STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 28 FEBRUARY 2025** |Unrestricted
Notes
funds
£
**INCOME AND ENDOWMENTS FROM**
Donations and legacies
2
3,292
**Charitable activities**
4
Charitable activities
145,193
Investment income
3
5,990
**Total**
154,475
**EXPENDITURE ON**
Raising funds
3,389
**Charitable activities**
Charitable activities
90,853
**Total**
94,242
**NET INCOME/(EXPENDITURE)**
Transfers between funds 12
60,233
-
**RECONCILIATION OF FUNDS**
Total funds brought forward
60,233
184,696
**TOTAL FUNDS CARRIED FORWARD**
244,929|Restricted
funds
£
-
25,000
-
25,000
-
63,524
63,524
(38,524)
-
(38,524)
64,621
26,097|2025
Total
2024
Total
funds
£
funds
£
3,292
51,297
170,193
50,000
5,990
53
179,475
101,350
3,389
418
154,377
148,494
157,766
148,912
21,709
-
(47,562)
-
21,709
249,317
(47,562)
296,879
271,026
249,317| |---|---|---| The notes form part of these financial statements Page 7 Docusign Envelope ID: EC3FB640-0F7C-4E77-9D43-EE00D5BA2BEF ## **ORCHARD** ## **BALANCE SHEET 28 FEBRUARY 2025** |||2025|2024| |---|---|---|---| |||Total|Total| |||funds|funds| ||Notes|£|£| |**CURRENT ASSETS**|||| |Debtors|10|323|297| |Cash at bank||271,688|250,433| |||272,011|250,730| |**CREDITORS**|||| |Amounts falling due within one year|11|(985)|(1,413)| |**NET CURRENT ASSETS**||271,026|249,317| |**TOTAL ASSETS LESS CURRENT LIABILITIES**||271,026|249,317| |**NET ASSETS**||271,026|249,317| |**FUNDS**|12||| |Unrestricted funds||244,929|184,696| |Restricted funds||26,097|64,621| |**TOTAL FUNDS**||271,026|249,317| The financial statements were approved by the Board of Trustees and authorised for issue on 04/07/2025 . ...................................... and were signed on its behalf by: ............................................. ABAAB50153274BF... Dr N T Sireau PhD - Trustee The notes form part of these financial statements Page 8 Docusign Envelope ID: EC3FB640-0F7C-4E77-9D43-EE00D5BA2BEF **ORCHARD** **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 28 FEBRUARY 2025** ## **1. ACCOUNTING POLICIES** ## **Basis of preparing the financial statements** The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention. ## **Income** All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably. ## **Expenditure** Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources. Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure. ## **Tangible fixed assets** Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life. Computer equipment - 33% on cost ## **Taxation** The charity is exempt from tax on its charitable activities. ## **Fund accounting** Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees. Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes. Further explanation of the nature and purpose of each fund is included in the notes to the financial statements. ## **Donated services** The value of donated services and gifts in kind provided to the Charity are recognised at their open market value in the period in which they are receivable as incoming resources, where the benefit to the charity can be reliably measured. ## **Debtors** Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due. continued... Page 9 Docusign Envelope ID: EC3FB640-0F7C-4E77-9D43-EE00D5BA2BEF **ORCHARD** **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 28 FEBRUARY 2025** ## **1. ACCOUNTING POLICIES - continued** ## **Cash at bank and in hand** Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account. ## **Creditors and provisions** Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be estimated or measured reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due. ## **Financial instruments** The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value. ## **2. DONATIONS AND LEGACIES** |**DONATIONS AND LEGACIES**||| |---|---|---| |Donations
Donated services and facilities|2025
£
3,292
-
3,292|2024
£
51,297
-| |||51,297| ## **3. INVESTMENT INCOME** |**INVESTMENT INCOME**||| |---|---|---| ||2025|2024| ||£|£| |Deposit account interest|5,990|53| Page 10 Docusign Envelope ID: EC3FB640-0F7C-4E77-9D43-EE00D5BA2BEF ## **ORCHARD** ## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 28 FEBRUARY 2025** ## **4. INCOME FROM CHARITABLE ACTIVITIES** |Activity
Grants
Charitable activities
Grants received, included in the above, are as follows:
WinTrust Foundation
National Lottery Fund
The Rowlands Trust
Medical Research Council
First Trust Services
**5.**
**GRANTS PAYABLE**
Charitable activities
The total grants paid during the year were as follows:
The University of Chicago
Downing College
Hertfordshire Partnership: FEATSOC study
Imperial College London: Psilocybin study
Orchard OCD & University of Cambridge
Contour Creative Display
TConsult Limited
|
|2025
2024
£
£
170,193
50,000
2025
2024
£
£
20,000
30,000
- 20,000
5,000
-
135,193
20,000
10,000
-
170,193
50,000
2025
2024
£
£
68,740
115,169
2025
2024
£
£
-
50,000
5,632
5,968
45,000
19,201
-
40,000
15,536
-
2,152
-
420
-
68,740 115,169| |---|---|---| ||
|| |||| ## **6. TRUSTEES' REMUNERATION AND BENEFITS** There were no trustees' remuneration or other benefits for the year ended 28 February 2025 nor for the year ended 29 February 2024. ## **Trustees' expenses** During the year no Trustee expenses were paid (2024: nil). ## **7. STAFF COSTS** |Wages and salaries
Social security costs
Pension

The average monthly number of employees during the year was as follows:
Head of Fundraising and Communications
No employees received emoluments in excess of £60,000.|2025
2024
£
£
21,712 22,967
-
-
786
541
22,498 23,508
2025
2024
1
1| |---|---| Page 11 Docusign Envelope ID: EC3FB640-0F7C-4E77-9D43-EE00D5BA2BEF **ORCHARD** **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 28 FEBRUARY 2025** ## **8. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES** ## **FOR THE YEAR ENDED 28 FEBRUARY 2024** |**INCOME AND ENDOWMENTS FROM**
Donations and legacies
**Charitable activities**
Charitable activities
Investment income
**Total**
**EXPENDITURE ON**
Raising funds
**Charitable activities**
Charitable activities
**Total**
**NET INCOME/(EXPENDITURE)**
**Transfers between funds**
**Net movement in funds**
**RECONCILIATION OF FUNDS**
Total funds brought forward
**TOTAL FUNDS CARRIED FORWARD**|Unrestricted funds
Restricted Funds
Total funds
£
£
£
51,297
-
51,297
-
50,000
50,000
53
-
53
51,350
50,000
101,350
418
-
418
85,933
62,561
148,494
86,351
62,561
148,912
35,001
-
12,561
-
47,562
-
11,042
11,042
-
-
23,959
-
23,603
-
47,562
-
208,655
88,224
296,879
184,696
64,621
249,317| |---|---| Page 12 Docusign Envelope ID: EC3FB640-0F7C-4E77-9D43-EE00D5BA2BEF ## **ORCHARD** ## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 28 FEBRUARY 2025** |**9.**
**TANGIBLE FIXED ASSETS**
**COST**
At 1 March 2024 and 28 February 2025
**DEPRECIATION**
At 1 March 2024 and 28 February 2025
**NET BOOK VALUE**
At 28 February 2025
At 29 February 2024
**10.**
**DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**
Prepayments and accrued income
**11.**
**CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**
Trade creditors
Other creditors||2025
£
323
2025
£
540
445
985|Computer
equipment
£
1,466
1,466
-
-
2024
£
297
2024
£
900
513
1,413| |---|---|---|---| ||||| Page 13 Docusign Envelope ID: EC3FB640-0F7C-4E77-9D43-EE00D5BA2BEF ## **ORCHARD** ## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 28 FEBRUARY 2025** ## **12. MOVEMENT IN FUNDS** |**Unrestricted funds**
General fund
Tolcapone Study
PhD into trauma and OCD
**Restricted funds**
Research into the efficacy of Psilocybin
Patient Registry
Awards for All
Video Project
OCD Workshop
**TOTAL FUNDS**
Net movement in funds, included in the
above are as follows:
**Unrestricted funds**
General fund
Tolcapone Study
PhD into trauma and OCD
**Restricted funds**
Research into the efficacy of Psilocybin
Patient Registry
Awards for All
OCD Workshop
**TOTAL FUNDS**|At 1/3/24
£
50,664
100,000
34,032
184,696
-
44,621
-
-
20,000
64,621
249,317|Net
movement
in funds
£
115,865
(50,000)
(5,632)
60,233
5,000
(25,000)
(18,144)
-
(380)
(38,524)
21,709
Incoming
resources
£
154,475
-
-
154,475
5,000
20,000
-
-
25,000
179,475|Transfers
between
At
funds
£
28/2/25
£
-
166,529
-
-
50,000
28,400
-
244,929
-
5,000
-
19,621
20,000
1,856
-
(20,000)
-
(380)
-
26,097
-
271,026
Resources
expended
£
Movement
in funds
£
(38,610)
(50,000)
(5,632)

115,865
(50,000)
(5,632)

(94,242)
-
(60,233)
5,000
(45,000) (25,000)
(18,144)
(18,144)
(380)
(380)
(63,524)
(38,524)
(157,766)
21,709| |---|---|---|---| Page 14 Docusign Envelope ID: EC3FB640-0F7C-4E77-9D43-EE00D5BA2BEF ## **ORCHARD** ## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 28 FEBRUARY 2025** ## **12. MOVEMENT IN FUNDS – continued** |**Comparatives for movement in funds**
**Unrestricted funds**
General fund
Tolcapone Study
PhD into trauma and OCD
**Restricted funds**
Research into the efficacy of Psilocybin
Patient Registry
Video Project
OCD Workshop
**TOTAL FUNDS**
Comparative net movement in funds, included
in the above are as follows:|At 1/3/23
£
73,655
135,000
-
208,655
51,042
32,182
5,000
-
88,224
296,879|Net
movement
in funds
£
20,967
(50,000)
(5,968)
(35,001)
(40,000)
7,439
-
20,000
(12,561)
(47,562)|Transfers
between
funds
£
(43,958)
15,000
40,000
11,042
(11,042)
5,000
(5,000)
-
(11,042)
-|At
29/2/24
£
50,664
100,000
34,032
184,696
-
44,621
-
20,000
64,621
249,317| |---|---|---|---|---| ||Incoming|Resources|Movement| |---|---|---|---| ||resources|expended|in funds| ||£|£|£| |**Unrestricted funds**|||| |General fund|51,350|(30,383)|20,967| |Tolcapone Study|-|(50,000)|(50,000)| |PhD into trauma and OCD|-|(5,968)
|(5,968)
| ||51,350|(86,351)|
(35,001)| |**Restricted funds**|||| |Research into the efficacy of Psilocybin|-|(40,000)|(40,000)| |Patient Registry|30,000|(22,561)|7,439| |OCD Workshop|20,000|-|20,000| ||50,000|(62,561)|(12,561)| |**TOTAL FUNDS**|101,350|(148,912)|(47,562)| Page 15 Docusign Envelope ID: EC3FB640-0F7C-4E77-9D43-EE00D5BA2BEF ## **ORCHARD** ## **NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 28 FEBRUARY 2025** ## Restricted funds - OCD workshop: this is a one-day workshop in London for OCD patients to find out about the latest scientific research into OCD with presentations in lay language by leading OCD researchers - Psilocybin Research Project: a study at Imperial College to test whether psilocybin by help with OCD symptoms. - Awards For All: a grant to organise a conference where leading OCD scientists presented their research to OCD patients and their families. ## Designated funds - Tolcapone Study: represents funds designated by the Trustees towards the studies being held with the University of Chicago. - PhD into trauma and OCD: research into the overlap between trauma and OCD ## **13. RELATED PARTY DISCLOSURES** During the year, Trustees and their related parties made donations totalling £nil (2024 £14,000). Page 16